Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Cytarabine 500mg/25ml solution for injection Cytosafe vials
0801030D0BFABAM
|
Cytarabine (Cytosafe) | Cytarabine | Malignant Disease and Immunosuppression | No data available |
|
Cytarabine 500mg/25ml solution for injection vials
0801030D0AAAMAM
|
Cytarabine | Cytarabine | Malignant Disease and Immunosuppression | No data available |
|
Cytarabine 500mg/5ml solution for injection vials
0801030D0AAAJAJ
|
Cytarabine | Cytarabine | Malignant Disease and Immunosuppression | No data available |
|
Cytarabine 5g/50ml solution for infusion vials
0801030D0AAAQAQ
|
Cytarabine | Cytarabine | Malignant Disease and Immunosuppression | No data available |
|
Cytoxan 25mg tablets
0801010H0BDAAAK
|
Cytoxan | Cyclophosphamide | Malignant Disease and Immunosuppression | No data available |
|
Dabrafenib 50mg capsules
0801050CUAAAAAA
|
Dabrafenib | Dabrafenib | Malignant Disease and Immunosuppression | No data available |
|
Dabrafenib 75mg capsules
0801050CUAAABAB
|
Dabrafenib | Dabrafenib | Malignant Disease and Immunosuppression | No data available |
|
Dacarbazine 100mg powder for solution for injection vials
0801050L0AAAAAA
|
Dacarbazine | Dacarbazine | Malignant Disease and Immunosuppression | No data available |
|
Dacarbazine 1g powder for solution for infusion vials
0801050L0AAAEAE
|
Dacarbazine | Dacarbazine | Malignant Disease and Immunosuppression | No data available |
|
Dacarbazine 200mg powder for solution for injection vials
0801050L0AAABAB
|
Dacarbazine | Dacarbazine | Malignant Disease and Immunosuppression | No data available |
|
Dacarbazine 500mg powder for solution for infusion vials
0801050L0AAADAD
|
Dacarbazine | Dacarbazine | Malignant Disease and Immunosuppression | No data available |
|
Dacarbazine 600mg powder for solution for infusion vials
0801050L0AAACAC
|
Dacarbazine | Dacarbazine | Malignant Disease and Immunosuppression | No data available |
|
Daclizumab 150mg/1ml inj pre-filled disposable devices
0802040AZAAAAAA
|
Daclizumab (Immunomodulating) | Daclizumab (Immunomodulating) | Malignant Disease and Immunosuppression | No data available |
|
Daclizumab 25mg/5ml solution for infusion vials
0802020V0AAAAAA
|
Daclizumab | Daclizumab | Malignant Disease and Immunosuppression | No data available |
|
Dacogen 50mg pdr for concentrate for inf vials
0801030AEBBAAAA
|
Dacogen | Decitabine | Malignant Disease and Immunosuppression | No data available |
|
Dacomitinib 15mg tablets
0801050CQAAAAAA
|
Dacomitinib | Dacomitinib | Malignant Disease and Immunosuppression | No data available |
|
Dacomitinib 30mg tablets
0801050CQAAABAB
|
Dacomitinib | Dacomitinib | Malignant Disease and Immunosuppression | No data available |
|
Dacomitinib 45mg tablets
0801050CQAAACAC
|
Dacomitinib | Dacomitinib | Malignant Disease and Immunosuppression | No data available |
|
Dactinomycin 500microgram inj vials
0801020D0AAAAAA
|
Dactinomycin | Dactinomycin | Malignant Disease and Immunosuppression | No data available |
|
Dasatinib 100mg tablets
0801050ANAAADAD
|
Dasatinib | Dasatinib | Malignant Disease and Immunosuppression | No data available |
|
Dasatinib 10mg/ml oral suspension
0801050ANAAAGAG
|
Dasatinib | Dasatinib | Malignant Disease and Immunosuppression | No data available |
|
Dasatinib 110.6mg tablets
0801050ANAAALAL
|
Dasatinib | Dasatinib | Malignant Disease and Immunosuppression | No data available |
|
Dasatinib 140mg tablets
0801050ANAAAEAE
|
Dasatinib | Dasatinib | Malignant Disease and Immunosuppression | No data available |
|
Dasatinib 15.8mg tablets
0801050ANAAAHAH
|
Dasatinib | Dasatinib | Malignant Disease and Immunosuppression | No data available |
|
Dasatinib 20mg tablets
0801050ANAAAAAA
|
Dasatinib | Dasatinib | Malignant Disease and Immunosuppression | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.